Australia markets closed

Virios Therapeutics, Inc. (VIRI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.05-0.51 (-7.77%)
At close: 04:00PM EST
6.41 +0.36 (+5.95%)
After hours: 04:14PM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.56
Open6.33
Bid5.52 x 800
Ask6.63 x 1000
Day's range5.54 - 6.47
52-week range4.00 - 8.79
Volume55,645
Avg. volume34,901
Market cap50.399M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.38
Earnings date12 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est16.33
  • Business Wire

    Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference

    ATLANTA, January 04, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022.

  • Business Wire

    Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia

    ATLANTA, December 01, 2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that more than 50% of the patients planned for the Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1) study have been randomized.

  • Business Wire

    Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

    ATLANTA, November 11, 2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, reported today financial results for the third quarter ended September 30, 2021 and provided a corporate update at 8:30 a.m. EST.